公司资料
United Therapeutics 股价、新闻与催化剂
- 股票代码:
- UTHR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
512.88 USD (-0.05%)
收盘价
最后更新: 2026年8月24日
22.9B USD
市值
股价为何变动
As of Aug 24, 2026, UTHR was little changed and closed at $512.88. No new same-company headline was identified in the current news window.
公司概览
业务概览
United Therapeutics is a biotechnology company focused on therapies for pulmonary arterial hypertension and other severe chronic conditions. Its business has long been anchored by a small number of highly differentiated commercial products and a pipeline aimed at expanding that footprint.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, United Therapeutics has a U.S.-centered commercial and development profile. It sits in specialty biotech with a strong rare-disease and pulmonary-hypertension identity.
商业模式特征
The company combines commercial product revenue with pipeline expansion, manufacturing discipline, and long-duration disease management. Investors watch product demand, label breadth, and whether the company can continue extending its franchise into new pulmonary indications.
生物医药行业定位
United Therapeutics occupies a premium niche within biotech because it has already proved it can commercialize highly specialized therapies. It remains catalyst-sensitive, but the business is more durable than a pure early-stage biotech name.
未来催化剂
- United Therapeutics’ next catalysts are Tyvaso DPI growth, pulmonary-hypertension expansion, and any additional inhaled-treprostinil data. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。